Beneficial Effect of Voluntary Exercise on Experimental Colitis in Mice Fed a High-Fat Diet: The Role of Irisin, Adiponectin and Proinflammatory Biomarkers

Inflammatory bowel diseases (IBDs) are a heterogeneous group of disorders exhibited by two major phenotypic forms: Crohn‘s disease and ulcerative colitis. Although the aetiology of IBD is unknown, several factors coming from the adipose tissue and skeletal muscles, such as cytokines, adipokines and myokines, were suggested in the pathogenesis of ulcerative colitis; however, it has not been extensively studied whether voluntary exercise can ameliorate that disorder. We explored the effect of moderate exercise (i.e., voluntary wheel running) on the disease activity index (DAI), colonic blood flow (CBF), plasma irisin and adiponectin levels and real-time PCR expression of proinflammatory markers in mesenteric fat in mice with 2,4,6-trinitrobenzenesulfonic acid (TNBS) colitis fed a high-fat diet (HFD) compared to those on a standard chow diet (SD). Macroscopic and microscopic colitis in sedentary SD mice was accompanied by a significant fall in CBF, some increase in colonic tissue weight and a significant increase in the plasma levels of tumour necrosis factor-alpha (TNF-α), IL-6, monocyte chemotactic protein 1 (MCP-1) and IL-13 (p < 0.05). In sedentary HFD mice, colonic lesions were aggravated, colonic tissue weight increased and the plasma TNF-α, IL-6, MCP-1, IL-1β and leptin levels significantly increased. Simultaneously, a significant decrease in the plasma irisin and adiponectin levels was observed in comparison with SD mice (p < 0.05). Exercise significantly decreased macroscopic and microscopic colitis, substantially increased CBF and attenuated the plasma TNF-α, IL-6, MCP-1, IL-1β and leptin levels while raising the plasma irisin and the plasma and WAT concentrations of adiponectin in HFD mice (p < 0.05). We conclude that: (1) experimental colitis is exacerbated in HFD mice, possibly due to a fall in colonic microcirculation and an increase in the plasma and mesenteric fat content of proinflammatory biomarkers; and (2) voluntary physical activity can attenuate the severity of colonic damage in mice fed a HFD through the release of protective irisin and restoration of plasma adiponectin.

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b

INTRODUCTION

Treatment of chronic hepatitis C (CHC) with pegylated interferon (Peg-IFN) and ribavirin leads to sustained virological response (SVR) in approximately 50% of the patients. SVR depends on hepatitis C virus (HCV) and host factors, including IL28B genotypes.

OBJECTIVES

The aim of the study was to investigate the therapeutic efficacy of the difficult-to-treat HCV genotype 1b in patients from the south of Poland.

PATIENTS AND METHODS

A total of 260 adult patients with CHC and HCV genotype 1b were treated with Peg-IFN alfa-2a or Peg-IFN alfa-2b with ribavirin for 48 weeks. Efficacy was assessed at 12 weeks (early virological response - EVR), 48 weeks (end-of-treatment response - ETR), and at 6 months (SVR). HCV-RNA, alanine transaminase (ALT), and other biochemical parameters were measured in serum at baseline and at 12, 48, and 72 weeks of therapy.

RESULTS

HCV-RNA levels were 3.72 ±1.17 × 106 IU/ml at baseline and decreased significantly at 12 weeks (0.02 ±0.17 × 106 IU/ml); there were no differences between the group treated with Peg-INF alfa-2a and the group treated with Peg-INF alfa-2b. ALT was 94.1 ±7.6 IU/l at baseline and decreased significantly at 12 weeks (42.5 ±3.1 IU/l). The overall EVR, ETR, and SVR were achieved by 63.9%, 77.7%, and 48.1% of the patients, respectively. Tolerance of therapy was similar in both groups.

CONCLUSIONS

Efficacy of Peg-IFN alfa-2a with ribavirin is not significantly different from that of Peg-IFN alfa-2b with ribavirin, and SVR was achieved in 48.3% and 44.3% of the patients, respectively. Our study confirms that the efficacy of treatment of patients with HCV genotype 1b from the southern region of Poland is similar to that observed in the overall Polish population.

Morphological changes of the upper gastrointestinal tract mucosa and Helicobacter pylori infection in HIV-positive patients with severe immunodeficiency and symptoms of dyspepsia

BACKGROUND

HIV infection causes progressive immune defense system dysfunction, including the gastrointestinal (GI) tract. The aim of the study was to evaluate the morphological changes in the upper-GI tract mucosa in HIV-infected patients in relation to the degree of immunodeficiency, presence of H. pylori, fungal colonization, and antiretroviral treatment (HAART).

MATERIAL/METHODS

One hundred forty-six patients (94 HIV positive, 52 HIV negative) with dyspeptic symptoms were evaluated by upper GI endoscopy and biopsy. The HIV-infected were divided into two groups: 47 patients with CD4+ count >200/mm(3) and 47 with severe immunodeficiency (CD4+ count <200/mm(3)); 42 of the total patients were treated with HAART. Gastric biopsies for histopathology and urease test, esophageal swabs, and gastric aspirates for mycological evaluation were taken.

RESULTS

The HIV-infected patients with severe immunodeficiency had a lower prevalence of H. pylori infection and active chronic gastritis in the gastric antrum compared with the other HIV-infected patients and controls (H. pylori in 40%, 72%, and 69%, respectively; p<0.05). Mycotic esophagitis and mycotic colonization of the stomach were more frequent in patients with severe immunodeficiency. The prevalence of gastric mucosa changes was not different between the patients treated and not treated with HAART; H. pylori infection was less frequent in HIV-infected patients treated with HAART (p<0.05).

CONCLUSIONS

In severely immunodeficient patients with dyspeptic symptoms, the prevalence of H. pylori and active chronic gastritis in the gastric antrum is much lower than in HIV-negative patients. H. pylori infection is less frequent in patients treated with HAART.

Clinical usefulness of probiotics in inflammatory bowel diseases

Probiotics are live nonpathogenic bacteria or bacterial components that may be helpful in the prevention and treatment of acute diarrhoea in adults and children and have some effects on the course of inflammatory bowel diseases (IBD). Many experimental and clinical studies suggest that intestinal bacterial flora plays an important role in the pathogenesis of IBD, and manipulation of the luminal contents with antibiotics or probiotics represents a potentially effective therapeutic option. The beneficial effect of probiotics was demonstrated mainly in the prevention and treatment of pouchitis and in maintaining remission of mild to moderate ulcerative colitis. Probiotics seems to be less effective in patients with Crohn's disease. Randomized clinical trials are still required to further define the role of probiotics as preventive and therapeutic agents. This review summarizes the current data about probiotics in IBD.